Canada - English - Health Canada

pharmascience inc - sotalol hydrochloride - tablet - 80mg - sotalol hydrochloride 80mg - beta-adrenergic blocking agents

Canada - English - Health Canada

pharmascience inc - sotalol hydrochloride - tablet - 160mg - sotalol hydrochloride 160mg - beta-adrenergic blocking agents

Canada - English - Health Canada

pharmascience inc - sotalol hydrochloride - tablet - 240mg - sotalol hydrochloride 240mg - beta-adrenergic blocking agents

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - tibolone, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; ascorbyl palmitate; potato starch; lactose monohydrate - short-term treatment of symptoms resulting from the natural or surgical menopause in post menopausal women. second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. after careful selection of users, xyvion should be prescribed for the shortest duration consistent with treatment goals. review the need for continuation of treatment after 6 months, taking into account the risk-benefit ratio for the individual user at the moment (including cardiovascular disease and breast cancer, refer clinical trials and precautions). xyvion should only be continued for as long as the benefit outweighs the risks.

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

aspen bad oldesloe gmbh - trimethoprim, sulfamethoxazole - suspension - 8mg/ml+40mg/ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

boehringer ingelheim pharma gmbh & co. kg - ipratropium bromide (ipratropium bromide monohydrate), fenoterol (fenoterol hydrobromide) - aerosol for inhalation, dosed - 20mcg/dose+ 50mcg/dose

Ireland - English - HPRA (Health Products Regulatory Authority)

johnson & johnson (ireland) limited - paracetamol; pseudoephedrine hydrochloride; diphenhydramine hydrochloride - film-coated tablet - 500 mg/12.5 mg/22.5 milligram(s) - anilides; paracetamol, combinations excl. psycholeptics

Ireland - English - HPRA (Health Products Regulatory Authority)

sofibel - bismuth oxide; zinc oxide; balsam peru; bismuth subgallate - suppository - 1 - other agents for treatment of hemorrhoids and anal fissures for topical use; zinc preparations

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - tibolone, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; potato starch; lactose monohydrate; ascorbyl palmitate - short-term treatment of symptoms resulting from the natural or surgical menopause in post menopausal women. second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. after careful selection of users, livial should be prescribed for the shortest duration consistent with treatment goals. review the need for continuation of treatment after 6 months, taking into account the risk-benefit ratio for the individual user at the moment (including cardiovascular disease and breast cancer, refer clinical trials and precautions). livial should only be continued for as long as the benefit outweighs the risks.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - tibolone, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; potato starch; ascorbyl palmitate; magnesium stearate; mannitol - - short-term treatment of symptoms resulting from the natural or surgical menopause in postmenopausal women.,- second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss.